Brief: Vaccinex Announces Initiation Of Single-Arm Open Label, Phase Ib/2 Study To Evaluate Pepinemab In Combination With Avelumab As Second Line Combination Immunotherapy For Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Pdac)
21/03/2023 12:39
March 21 (Reuters) - Vaccinex Inc VCNX.O :
* VACCINEX ANNOUNCES INITIATION OF SINGLE-ARM OPEN LABEL,
PHASE
IB/2 STUDY TO EVALUATE PEPINEMAB IN COMBINATION WITH AVELUMAB AS
SECOND LINE COMBINATION IMMUNOTHERAPY FOR PATIENTS WITH
METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
* VACCINEX INC: VACCINEX-SPONSORED STUDY WILL BE CONDUCTED
AT
UNIVERSITY OF ROCHESTER
* VACCINEX INC: PRIMARY FUNDING SUPPORT IS PROVIDED BY
GATEWAY
DISCOVERY AWARD, ADMINISTERED BY ASCO'S "CONQUER CANCER
FOUNDATION"
* VACCINEX INC: STUDY IS INTENDED TO ASSESS WHETHER
PEPINEMAB CAN
REVERSE SUPPRESSIVE TUMOR MICROENVIRONMENT FOUND IN PDAC
Source text for Eikon: ID:nGNX9Ggr5Y
Further company coverage: VCNX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease